Researchers at Massachusetts General Hospital in Boston have announced a five-year, $30 million deal with pharmaceutical giant Johnson & Johnson to bring to market an experimental test that detects cancer in the blood stream.
The test uses a microchip to detect tiny traces of cancer cells in blood, and helps doctors determine how well a cancer treatment is working. Researchers hope the test will one day become a “liquid biopsy,” replacing the painful tissue sampling used today. We speak with Dr. Mehmet Toner of MGH.
- Here & Now: Cancer death rates falling, but cure ellusive